Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study Academic Article uri icon

Overview

MeSH Major

  • Amyloidosis
  • Antineoplastic Agents, Alkylating
  • Hematopoietic Stem Cell Transplantation
  • Immunoglobulin Light Chains
  • Melphalan
  • Myeloablative Agonists

abstract

  • Post-transplantation survival in AL has improved, with a dramatic reduction in early post-transplantation mortality and excellent 5-year survival. The risk-benefit ratio for autotransplantation has changed, and randomized comparison with nontransplantation approaches is again warranted.

authors

publication date

  • November 10, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4737858

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.62.4015

PubMed ID

  • 26371138

Additional Document Info

start page

  • 3741

end page

  • 9

volume

  • 33

number

  • 32